Abstract:The coronavirus papain-like protease (PLpro) is crucial for viral replicase polyprotein processing. Additionally, PLpro can subvert host defense mechanisms by its deubiquitinating (DUB) and deISGylating activities. To elucidate the role of these activities during SARS-CoV-2 infection, we introduced mutations that disrupt binding of PLpro to ubiquitin or ISG15. We identified several mutations that strongly reduced DUB activity of PLpro, without affecting viral polyprotein processing. In contrast, mutations that abrogated deISGylating activity also hampered viral polyprotein processing and when introduced into the virus these mutants were not viable. SARS-CoV-2 mutants exhibiting reduced DUB activity elicited a stronger interferon response in human lung cells. In a mouse model of severe disease, disruption of PLpro DUB activity did not affect lethality, virus replication, or innate immune responses in the lungs. This suggests that the DUB activity of SARS-CoV-2 PLpro is dispensable for virus replication and does not affect innate immune responses in vivo . Interestingly, the DUB mutant of SARS-CoV replicated to slightly lower titers in mice and elicited a diminished immune response early in infection, although lethality was unaffected. We previously showed that a MERS-CoV mutant deficient in DUB and deISGylating activity was strongly attenuated in mice. Here, we demonstrate that the role of PLpro DUB activity during infection can vary considerably between highly pathogenic coronaviruses. Therefore, careful considerations should be taken when developing pan-coronavirus antiviral strategies targeting PLpro. The COVID-19 pandemic highlighted the need for pan-coronavirus targeting antivirals and vaccines. One of the potential targets is the viral papain-like protease (PLpro). PLpro is required for processing of the viral replicase polyprotein, thus enabling virus replication, but it also contributes to immune evasion by its deubiquitinating and deISGylating activities. Here we show that the deubiquitinating activity of SARS-CoV-2 PLpro does not influence virus replication, innate immune responses or lethality in mice. For SARS-CoV, we found that a mutant virus lacking deubiquitinating activity replicated to slightly lower titers and elicited a diminished immune response. This is in strong contrast to our previous findings for MERS-CoV, where removal of the deubiquitinating and deISGylating activities of PLpro strongly attenuated the virus in mice, completely alleviating lethality, and rendered it a promising live-attenuated vaccine candidate. This study uncovers important differences between highly pathogenic coronaviruses in the differential roles of PLpro during infection. These mechanistic insights provide valuable information for the development of pan-coronavirus targeting antivirals and vaccines.

The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING

Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways.

The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression

Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro

SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6

SARS-CoV-2 Papain-like Protease Negatively Regulates the NLRP3 Inflammasome Pathway and Pyroptosis by Reducing the Oligomerization and Ubiquitination of ASC

SARS-CoV-2 papain-like protease inhibits ISGylation of the viral nucleocapsid protein to evade host anti-viral immunity

Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo

The Main Protease of SARS-CoV-2 Cleaves Histone Deacetylases and DCP1A, Attenuating the Immune Defense of the Interferon-Stimulated Genes

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‐2 papain-like protease

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2

Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins

Coronaviruses using different strategies to antagonize antiviral responses and pyroptosis

P53 Degradation by a Coronavirus Papain-like Protease Suppresses Type I Interferon Signaling*

SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone

SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein–Protein Interactions

SARS-CoV-2 NSP8 suppresses type I and III IFN responses by modulating the RIG-I/MDA5, TRIF, and STING signaling pathways

SARS‐CoV‐2 NSP7 inhibits type I and III IFN production by targeting the RIG‐I/MDA5, TRIF, and STING signaling pathways